We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Most Drugmakers Filed Timely Reports on Postmarket Studies in 2020, FDA Says
Most Drugmakers Filed Timely Reports on Postmarket Studies in 2020, FDA Says
The FDA’s latest annual report on the postmarket performance of drug and biologics firms, which covers the fiscal year Oct. 2, 2019, to Sept. 30, 2020, says 75 percent of the 816 unique postmarket requirements (PMRs) and postmarket commitments (PMCs) in the FDA’s system were on schedule. But the agency said many of the studies failed to file timely reports.